Trial · NCT02248220
Efficacy and Tolerability of Sifrol® (Pramipexole) in Patients With Advanced Idiopathic Parkinson's Disease
NCT02248220, Completed, Boehringer Ingelheim
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Efficacy and Tolerability of Sifrol® (Pramipexole) in Patients With Advanced Idiopathic Parkinson's Disease. Trials, record NCT02248220. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02248220
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Efficacy and Tolerability of Sifrol® (Pramipexole) in Patients With Advanced Idiopathic Parkinson's Disease
- NCT number
- NCT02248220
- Status
- Completed
- Enrollment
- 657 participants, actual
- Lead sponsor
- Boehringer Ingelheim
- Conditions
- Parkinson Disease
- Interventions
- Pramipexole
- First posted
- 2014-09-25
- Last updated
- 2014-09-25
Source ClinicalTrials.gov
Registered outcomes11
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in cumulative daily doses of Sifrol® | up to 8 weeks | Changes in the doses between visits are evaluated using Wilcoxon's signed rank test |
| Primary | Changes in cumulative daily doses of L-dopa | up to 8 weeks | Changes in the doses between visits are evaluated using Wilcoxon's signed rank test |
| Secondary | Change from Baseline in Short Parkinson Evaluation Scale (SPES) total score | Baseline, after 8 weeks | |
| Secondary | Change from Baseline in SPES subscales | Baseline, after 8 weeks | Psychopathological disturbances, Activities of daily living, Evaluation of motor function, Tremor, Resting Tremor, Postural tremor, Complications of therapy |
| Secondary | Change from Baseline in Snaith-Hamilton-Pleasure-Scale total score | Baseline, after 8 weeks | patients with SPES depression \>= 2 |
| Secondary | Change from Baseline in Tremor Impact Scale (TIS-D) total score | Baseline, after 8 weeks | |
| Secondary | Change from Baseline in global Parkinson's Disease (PD) symptoms | Baseline, after 8 weeks | Akinesia, anhedonia, depression, dyskinesia, motor fluctuation, cognitive disturbances, rigor and tremor |
| Secondary | Global assessment of efficacy by investigator on a 5-point scale | after 8 weeks | |
| Secondary | Global assessment of tolerability by investigator on a 5-point scale | after 8 weeks | |
| Secondary | Number of patients with adverse events | up to 8 weeks |
1 to 10 of 11Source ClinicalTrials.gov
See all 11 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02248220
GET https://conductscience.org/api/trials/v1/NCT02248220/registered